Improved Survival of Incident Patients with High-Volume Haemodiafiltration: A Propensity-Matched Cohort Study with Inverse Probability of Censoring Weighting

被引:17
作者
Canaud, Bernard [1 ]
Bayh, Inga [1 ]
Marcelli, Daniele [1 ]
Ponce, Pedro [2 ]
Merello, Jose Ignacio [3 ]
Gurevich, Konstantin [4 ]
Ladanyi, Erzsebet [5 ]
Ok, Ercan [6 ]
Imamovic, Goran [7 ]
Grassmann, Aileen [1 ]
Scatizzi, Laura [1 ]
Gatti, Emanuele [1 ,8 ]
机构
[1] Fresenius Med Care, DE-61352 Bad Homburg, Germany
[2] NephroCare Portugal, Lisbon, Portugal
[3] NephroCare Spain, Madrid, Spain
[4] NephroCare Russia, St Petersburg, Russia
[5] NephroCare Hungary, Miskolc, Hungary
[6] NephroCare Turkey, Izmir, Turkey
[7] NephroCare Bosnia & Herzegovina, Zvornik, Bosnia & Herceg
[8] Danube Univ, Krems, Austria
关键词
Dialysis; Haemodialysis; Incident patients; IPCW; Propensity score; Survival; PATIENTS RECEIVING HEMODIAFILTRATION; ALL-CAUSE MORTALITY; ONLINE HEMODIAFILTRATION; HEMODIALYSIS; DIALYSIS; EPIDEMIOLOGY; INFLAMMATION; DATABASE; THERAPY; DISEASE;
D O I
10.1159/000371446
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Haemodiafiltration (HDF) is the preferred dialysis modality in many countries. The aim of the study was to compare the survival of incident patients on high-volume HDF (HV-HDF) with high-flux haemodialysis (HD) in a large-scale European dialysis population. Methods:The study population was extracted from 47,979 patients in 369 Nephro-Care centres throughout 12 countries. Baseline was six months after dialysis initiation; maximum follow-up was 5 years. Patients were either on HV-HDF (defined as with >= 21 litres substitution fluid volume per session) or on HD if on that treatment for of the 3 months before baseline. The main predictor was treatment modality. Other parameters included country, age, gender, BMI, haemoglobin, albumin and Charlson comorbidity index. Propensity score matching and Inverse Probability of Censoring Weighting (IPCW) were applied to reduce bias by indication and consider modality crossover, respectively. Results: After propensity score matching, 1,590 incident patients remained. Kaplan-Meier and proportional Cox regression analyses revealed no significant survival advantage of HV-HDF. Results were biased by modality crossover: during the 5-year study period, 7% of HV-HDF patients switched to HD, and 55% of HD patients switched to HV-HDF. IPCW uncovered a statistically significant survival advantage of HV-HDF (OR 0.501; CI 0.366-0.684; p < 0.001). A higher benefit of HV-HDF for some subgroups was revealed, for example, non-diabetics, patients 65-74 years, patients with obesity or high blood pressure. Conclusions: This large-scale study supports the generalizability of previous RCT findings regarding the survival benefit of HV-HDF. Sub-group analysis showed that some sub-cohorts appear to benefit more from HV-HDF than others. (C) 2015 S. Karger AG, Basel
引用
收藏
页码:179 / 188
页数:10
相关论文
共 28 条
[1]  
[Anonymous], EV 2 LIN TREATM ADV
[2]   Mortality risk for patients receiving hemodiafiltration versus hemodialysis: European results from the DOPPS [J].
Canaud, B. ;
Bragg-Gresham, J. L. ;
Marshall, M. R. ;
Desmeules, S. ;
Gillespie, B. W. ;
Depner, T. ;
Klassen, P. ;
Port, F. K. .
KIDNEY INTERNATIONAL, 2006, 69 (11) :2087-2093
[3]   The ESHOL study: hemodiafiltration improves survival-but how? [J].
Farrington, Ken ;
Davenport, Andrew .
KIDNEY INTERNATIONAL, 2013, 83 (06) :979-981
[4]   Results from EuCliD® (European clinical dialysis database):: Impact of shifting treatment modality [J].
Godino, JIM ;
Rentero, R ;
Orlandini, G ;
Marcelli, D ;
Ronco, C .
INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 2002, 25 (11) :1049-1060
[5]   Ionic dialysance measurement is urea distribution volume dependent: A new approach to better results [J].
Goldau, R ;
Kuhlmann, U ;
Samadi, N ;
Gross, M ;
Graf, T ;
Orlandini, G ;
Marcelli, D ;
Lange, H .
ARTIFICIAL ORGANS, 2002, 26 (04) :321-332
[6]   Effect of Online Hemodiafiltration on All-Cause Mortality and Cardiovascular Outcomes [J].
Grooteman, Muriel P. C. ;
van den Dorpel, Marinus A. ;
Bots, Michiel L. ;
Penne, E. Lars ;
van der Weerd, Neelke C. ;
Mazairac, Albert H. A. ;
den Hoedt, Claire H. ;
van der Tweel, Ingeborg ;
Levesque, Renee ;
Nube, Menso J. ;
ter Wee, Piet M. ;
Blankestijn, Peter J. .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2012, 23 (06) :1087-1096
[7]   Randomized Clinical Trials and Observational Studies Guidelines for Assessing Respective Strengths and Limitations [J].
Hannan, Edward L. .
JACC-CARDIOVASCULAR INTERVENTIONS, 2008, 1 (03) :211-217
[8]   Survival of incident patients on high-volume online hemodiafiltration compared to low-volume online hemodiafiltration and high-flux hemodialysis [J].
Imamovic, Goran ;
Hrvacevic, Rajko ;
Kapun, Sonja ;
Marcelli, Daniele ;
Bayh, Inga ;
Grassmann, Aileen ;
Scatizzi, Laura ;
Maslovaric, Jelena ;
Canaud, Bernard .
INTERNATIONAL UROLOGY AND NEPHROLOGY, 2014, 46 (06) :1191-1200
[9]   Longer-Term Outcomes of Letrozole Versus Placebo After 5 Years of Tamoxifen in the NCIC CTG MA.17 Trial: Analyses Adjusting for Treatment Crossover [J].
Jin, Huan ;
Tu, Dongsheng ;
Zhao, Naiqing ;
Shepherd, Lois E. ;
Goss, Paul E. .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (07) :718-721
[10]  
Jirka T, 2006, KIDNEY INT, V70, P1524, DOI 10.1038/sj.ki.5001759